Scalper1 News
Big-cap biotech leaders Biogen Idec and Gilead Sciences easily beat second-quarter earnings estimates and received product approvals Wednesday, but their stocks reacted very differently. Biogen (BIIB) earnings rose 52% vs. a year earlier to $3.49 a share, topping analysts’ consensus by 66 cents. Sales grew 40% to $2.4 billion vs. the Street’s $2.16 billion. The company increased its full-year revenue range for 38%-41% growth from Scalper1 News
Scalper1 News